| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 23 | 2025 | 529 | 5.990 |
Why?
|
| Methotrexate | 5 | 2025 | 336 | 2.330 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2025 | 185 | 1.960 |
Why?
|
| Antineoplastic Agents | 8 | 2025 | 1714 | 1.740 |
Why?
|
| Cyclopentanes | 2 | 2024 | 20 | 1.630 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2020 | 774 | 1.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2025 | 1245 | 1.330 |
Why?
|
| Pyrimidines | 2 | 2024 | 375 | 1.320 |
Why?
|
| Neoplasms | 7 | 2025 | 2794 | 1.180 |
Why?
|
| Transplantation Conditioning | 2 | 2020 | 279 | 1.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 260 | 1.080 |
Why?
|
| Hepatoblastoma | 3 | 2024 | 180 | 1.060 |
Why?
|
| Child | 42 | 2025 | 24614 | 1.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2022 | 1097 | 0.980 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 426 | 0.920 |
Why?
|
| Induction Chemotherapy | 3 | 2022 | 42 | 0.890 |
Why?
|
| Child, Preschool | 24 | 2025 | 14152 | 0.860 |
Why?
|
| Pediatrics | 4 | 2022 | 1158 | 0.850 |
Why?
|
| Adolescent | 25 | 2025 | 19419 | 0.810 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 1026 | 0.770 |
Why?
|
| Algorithms | 3 | 2025 | 1630 | 0.740 |
Why?
|
| Liver Neoplasms | 4 | 2024 | 1316 | 0.730 |
Why?
|
| Legislation, Drug | 1 | 2020 | 9 | 0.710 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 31 | 0.710 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2020 | 32 | 0.690 |
Why?
|
| Neuroendocrine Tumors | 1 | 2021 | 54 | 0.690 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 25 | 0.680 |
Why?
|
| Off-Label Use | 2 | 2025 | 28 | 0.670 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 79 | 0.670 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 91 | 0.660 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 56 | 0.660 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 544 | 0.630 |
Why?
|
| Orchiectomy | 1 | 2019 | 51 | 0.630 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2019 | 19 | 0.620 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 50 | 0.610 |
Why?
|
| Humans | 54 | 2025 | 125116 | 0.610 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 6 | 0.610 |
Why?
|
| Neutropenia | 1 | 2020 | 196 | 0.610 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2025 | 1155 | 0.600 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2021 | 122 | 0.600 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2019 | 145 | 0.600 |
Why?
|
| Periosteum | 1 | 2019 | 33 | 0.600 |
Why?
|
| Radiotherapy | 1 | 2019 | 138 | 0.600 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 94 | 0.600 |
Why?
|
| Hearing Loss | 3 | 2025 | 136 | 0.600 |
Why?
|
| Alemtuzumab | 1 | 2018 | 86 | 0.590 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 587 | 0.590 |
Why?
|
| Quinazolines | 1 | 2019 | 174 | 0.590 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 134 | 0.580 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 66 | 0.580 |
Why?
|
| Organophosphonates | 1 | 2018 | 20 | 0.580 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 117 | 0.580 |
Why?
|
| Doxorubicin | 1 | 2019 | 288 | 0.570 |
Why?
|
| Cytosine | 1 | 2018 | 57 | 0.570 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 145 | 0.570 |
Why?
|
| Cystitis | 1 | 2018 | 42 | 0.560 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 146 | 0.560 |
Why?
|
| Bacterial Infections | 1 | 2020 | 304 | 0.560 |
Why?
|
| BK Virus | 1 | 2018 | 60 | 0.560 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 161 | 0.550 |
Why?
|
| Infection Control | 1 | 2018 | 145 | 0.550 |
Why?
|
| Polyomavirus Infections | 1 | 2018 | 90 | 0.540 |
Why?
|
| Tumor Virus Infections | 1 | 2018 | 134 | 0.540 |
Why?
|
| Infant | 17 | 2025 | 12610 | 0.540 |
Why?
|
| Osteosarcoma | 1 | 2019 | 255 | 0.540 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 323 | 0.530 |
Why?
|
| Apoptosis | 2 | 2021 | 1819 | 0.500 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1237 | 0.490 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 277 | 0.480 |
Why?
|
| Female | 28 | 2025 | 66709 | 0.480 |
Why?
|
| Thoracic Wall | 1 | 2015 | 39 | 0.480 |
Why?
|
| Survival Rate | 5 | 2024 | 2051 | 0.480 |
Why?
|
| Prognosis | 8 | 2025 | 4684 | 0.470 |
Why?
|
| Male | 25 | 2025 | 61448 | 0.470 |
Why?
|
| Cisplatin | 3 | 2025 | 250 | 0.470 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 174 | 0.450 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 1654 | 0.450 |
Why?
|
| Retrospective Studies | 16 | 2025 | 16342 | 0.450 |
Why?
|
| Follow-Up Studies | 8 | 2025 | 5169 | 0.420 |
Why?
|
| Young Adult | 10 | 2025 | 9058 | 0.420 |
Why?
|
| Sarcoma | 1 | 2015 | 184 | 0.420 |
Why?
|
| Disease Management | 1 | 2017 | 528 | 0.420 |
Why?
|
| NEDD8 Protein | 2 | 2024 | 11 | 0.420 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 1833 | 0.400 |
Why?
|
| Antiviral Agents | 1 | 2018 | 767 | 0.390 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2025 | 1684 | 0.380 |
Why?
|
| Cell Proliferation | 1 | 2019 | 2377 | 0.380 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2022 | 69 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1265 | 0.340 |
Why?
|
| Drug Monitoring | 2 | 2025 | 172 | 0.330 |
Why?
|
| Drug Therapy | 1 | 2020 | 87 | 0.320 |
Why?
|
| Proton Therapy | 2 | 2022 | 126 | 0.320 |
Why?
|
| Emergencies | 1 | 2020 | 172 | 0.300 |
Why?
|
| Treatment Outcome | 5 | 2025 | 12273 | 0.300 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 121 | 0.280 |
Why?
|
| Maximum Tolerated Dose | 2 | 2025 | 163 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 914 | 0.280 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 150 | 0.270 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 880 | 0.250 |
Why?
|
| Thiosulfates | 1 | 2025 | 6 | 0.240 |
Why?
|
| Cell Line, Tumor | 3 | 2022 | 3422 | 0.230 |
Why?
|
| Biopsy | 2 | 2018 | 1242 | 0.230 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 272 | 0.210 |
Why?
|
| Medical Oncology | 2 | 2022 | 220 | 0.210 |
Why?
|
| Dexamethasone | 1 | 2025 | 271 | 0.210 |
Why?
|
| United States | 5 | 2024 | 10884 | 0.210 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2022 | 64 | 0.210 |
Why?
|
| Prospective Studies | 4 | 2022 | 6123 | 0.190 |
Why?
|
| Tracheostomy | 1 | 2024 | 196 | 0.190 |
Why?
|
| Incidence | 3 | 2024 | 3131 | 0.190 |
Why?
|
| Thoracic Neoplasms | 1 | 2021 | 37 | 0.190 |
Why?
|
| Ganglioneuroblastoma | 1 | 2021 | 6 | 0.190 |
Why?
|
| Ganglioneuroma | 1 | 2021 | 17 | 0.190 |
Why?
|
| Polypharmacy | 1 | 2021 | 40 | 0.180 |
Why?
|
| MyoD Protein | 1 | 2021 | 24 | 0.180 |
Why?
|
| Radioisotopes | 1 | 2021 | 38 | 0.180 |
Why?
|
| Drug Interactions | 1 | 2022 | 254 | 0.180 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 149 | 0.180 |
Why?
|
| Receptors, Peptide | 1 | 2021 | 50 | 0.180 |
Why?
|
| Government Regulation | 1 | 2020 | 41 | 0.180 |
Why?
|
| Infusions, Intravenous | 2 | 2025 | 552 | 0.170 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 168 | 0.170 |
Why?
|
| Risk Factors | 3 | 2019 | 10282 | 0.170 |
Why?
|
| Animals | 6 | 2022 | 34303 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 734 | 0.170 |
Why?
|
| Fatty Acids | 1 | 2022 | 344 | 0.170 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 143 | 0.160 |
Why?
|
| Medication Errors | 1 | 2021 | 186 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 101 | 0.160 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 728 | 0.160 |
Why?
|
| Vincristine | 1 | 2020 | 191 | 0.160 |
Why?
|
| Etoposide | 1 | 2019 | 115 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2020 | 173 | 0.160 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 306 | 0.160 |
Why?
|
| Vocal Cord Paralysis | 1 | 2020 | 67 | 0.160 |
Why?
|
| Sodium | 1 | 2020 | 297 | 0.160 |
Why?
|
| Drug Synergism | 1 | 2019 | 226 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 174 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 348 | 0.150 |
Why?
|
| Cell Cycle | 1 | 2021 | 627 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 186 | 0.150 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 191 | 0.150 |
Why?
|
| Tumor Burden | 1 | 2019 | 231 | 0.150 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 96 | 0.150 |
Why?
|
| Administration, Intravesical | 1 | 2018 | 33 | 0.150 |
Why?
|
| Adult | 7 | 2025 | 29465 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 376 | 0.150 |
Why?
|
| Gangliosides | 1 | 2018 | 72 | 0.150 |
Why?
|
| Tissue Distribution | 1 | 2018 | 391 | 0.140 |
Why?
|
| Wilms Tumor | 1 | 2019 | 117 | 0.140 |
Why?
|
| Desensitization, Immunologic | 1 | 2019 | 103 | 0.140 |
Why?
|
| Allografts | 1 | 2018 | 176 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 276 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2019 | 312 | 0.140 |
Why?
|
| Mice, Nude | 1 | 2019 | 725 | 0.140 |
Why?
|
| Lower Extremity | 1 | 2019 | 178 | 0.140 |
Why?
|
| Mucositis | 1 | 2017 | 19 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 746 | 0.130 |
Why?
|
| Bone Marrow | 1 | 2018 | 323 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 290 | 0.130 |
Why?
|
| Risk | 1 | 2018 | 759 | 0.130 |
Why?
|
| Anticoagulants | 1 | 2021 | 576 | 0.130 |
Why?
|
| Thrombosis | 1 | 2021 | 520 | 0.130 |
Why?
|
| Area Under Curve | 1 | 2017 | 319 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2020 | 1395 | 0.130 |
Why?
|
| Fluid Therapy | 1 | 2017 | 129 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 933 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 620 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2020 | 678 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 780 | 0.120 |
Why?
|
| Acute Disease | 1 | 2018 | 1095 | 0.120 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8275 | 0.120 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 503 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 2414 | 0.110 |
Why?
|
| Cytokines | 1 | 2018 | 1292 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 373 | 0.100 |
Why?
|
| Age Factors | 1 | 2018 | 2815 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2020 | 4597 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 649 | 0.080 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 621 | 0.080 |
Why?
|
| Mice | 2 | 2021 | 17739 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2012 | 516 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 398 | 0.060 |
Why?
|
| Injection, Intratympanic | 1 | 2025 | 2 | 0.060 |
Why?
|
| Costa Rica | 1 | 2025 | 14 | 0.060 |
Why?
|
| Topotecan | 1 | 2025 | 48 | 0.060 |
Why?
|
| Gels | 1 | 2025 | 69 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2005 | 256 | 0.060 |
Why?
|
| Aspirin | 1 | 2005 | 222 | 0.050 |
Why?
|
| Piperidines | 1 | 2025 | 208 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2005 | 605 | 0.050 |
Why?
|
| Indazoles | 1 | 2022 | 25 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2005 | 265 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2025 | 412 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2025 | 306 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 760 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1071 | 0.050 |
Why?
|
| Protons | 1 | 2022 | 93 | 0.050 |
Why?
|
| Benzamides | 1 | 2022 | 110 | 0.050 |
Why?
|
| Dosage Forms | 1 | 2021 | 9 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2012 | 1178 | 0.050 |
Why?
|
| Bays | 1 | 2021 | 6 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 130 | 0.050 |
Why?
|
| Medication Reconciliation | 1 | 2021 | 14 | 0.050 |
Why?
|
| Drug Storage | 1 | 2021 | 17 | 0.050 |
Why?
|
| Pamphlets | 1 | 2021 | 22 | 0.050 |
Why?
|
| Maternal Age | 1 | 2022 | 134 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 473 | 0.050 |
Why?
|
| Communication Barriers | 1 | 2021 | 37 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2022 | 214 | 0.050 |
Why?
|
| Thoracoscopy | 1 | 2021 | 43 | 0.050 |
Why?
|
| Nonprescription Drugs | 1 | 2021 | 47 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2022 | 176 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3047 | 0.050 |
Why?
|
| Cranial Irradiation | 1 | 2021 | 69 | 0.040 |
Why?
|
| SEER Program | 1 | 2022 | 202 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2005 | 671 | 0.040 |
Why?
|
| Operative Time | 1 | 2021 | 165 | 0.040 |
Why?
|
| Health Literacy | 1 | 2021 | 75 | 0.040 |
Why?
|
| Quinolines | 1 | 2021 | 103 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 99 | 0.040 |
Why?
|
| Hoarseness | 1 | 2020 | 13 | 0.040 |
Why?
|
| Language | 1 | 2021 | 195 | 0.040 |
Why?
|
| Imidazoles | 1 | 2021 | 206 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2020 | 70 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 1 | 2019 | 6 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 559 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 1362 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2019 | 240 | 0.040 |
Why?
|
| Registries | 1 | 2024 | 1434 | 0.040 |
Why?
|
| Allergens | 1 | 2019 | 252 | 0.030 |
Why?
|
| Caregivers | 1 | 2021 | 540 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 2656 | 0.030 |
Why?
|
| Kidney | 1 | 2022 | 1360 | 0.030 |
Why?
|
| Parents | 1 | 2021 | 1024 | 0.030 |
Why?
|
| Texas | 1 | 2022 | 3571 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1520 | 0.030 |
Why?
|
| Hawaii | 1 | 2012 | 6 | 0.030 |
Why?
|
| Publications | 1 | 2012 | 33 | 0.020 |
Why?
|
| Faculty | 1 | 2012 | 102 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 219 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 4822 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7221 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 5906 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 19661 | 0.020 |
Why?
|
| Mathematical Computing | 1 | 2005 | 9 | 0.020 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2005 | 10 | 0.020 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2005 | 15 | 0.020 |
Why?
|
| Premedication | 1 | 2005 | 41 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 2005 | 120 | 0.010 |
Why?
|
| Middle Aged | 1 | 2024 | 26682 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2005 | 309 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2005 | 180 | 0.010 |
Why?
|
| Homozygote | 1 | 2005 | 547 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 810 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2005 | 325 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 802 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 1617 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 2570 | 0.010 |
Why?
|